Thyroid Gland; NodeSWIDDICHNCT02378246
Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study
A study testing Iodine in people with Thyroid Gland; Node and Pregnancy, run by Göteborg University at 4 sites in Sweden.
Trial summary
THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should a tablet with vitamins and minerals, including 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Thyroid Gland; Node, Pregnancy, Cognitive Developmental Delay
- What is being tested?
- Iodine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,337 participants
- Where
- 4 sitesSweden
- Study dates
- Nov 2012to Jun 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Pregnant, week <13
- Age 18-40 years
- Intent of a full term pregnancy
- Agreement of taking no iodide containing supplements during the study except for study supplement
- Age 18-40 years
- Agreeing not to take iodide containing supplements 1 week prior to the collecting of the samples.
Who cannot join
- Known current thyroid disease
- Risk factors for thyroid disease (history or heredity for thyroid, other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
- Possibility to not attend to the protocol according to the investigator's opinion
- Less than 6 months from previous pregnancy or lactating period
- Vegan
- CONTROL WOMEN
Show all 12Show fewer
- Current thyroid disease
- Risk factors for thyroid disease (history or heredity for thyroid or other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
- Possibility to not attend to the protocol according to the investigator's opinion
- Currently pregnant or lactating
- Less than 6 months from previous pregnancy or lactating period
- Vegans
Trial locations and contacts
4 sites in 1 country.
Sweden4 sites
Sahlgrenska University Hospital
Gothenburg, 413 45
Linköping University Hospital
Linköping, 581 85
Study site
Skövde
Umeå Universitet, Department of Clinical Sciences
Umeå, Västerbotten County, 901 85
About this study
Official title: The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study
THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should a tablet with vitamins and minerals, including 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID and no extra iodine is needed?". To answer this question, the investigators planned a randomized, placebo-controlled trial of micronutrient supplementation during pregnancy in Sweden (SWIDDICH) with the follow-up of childrens' COGNITIVE DEVELOPMENT at 18 months, 3.5, 7 and 14 years.
Iodine deficiency (ID) is associated with thyroid morbidity and, especially in children, with impaired cognitive development. Sweden introduced iodine fortification of table salt 1936 and mental retardation due to severe ID is eradicated. Is mild ID during pregnancy also eradicated? If not, is this of importance? A national study performed by the investigators in 2007 showed iodine sufficiency in general population, but there are no pregnancy data. Local studies have raised concerns for mild ID during pregnancy in Sweden and a trans-sectional national study is currently ongoing.
Read more
The burning question for Sweden and the whole world is: is mild ID during pregnancy of importance for the developing brain of the fetus? Two large observational studies have shown association between mild ID during pregnancy and lower verbal IQ or educational performance at school-aged children. The world needs a randomized placebo-controlled trial (RTC) comparing the cognitive outcome in children exposed to mild ID during fetal life with children exposed to normal iodine levels during fetal life.
Our HYPOTHESIS is that pregnant women in Sweden have mild ID and that children exposed to mild ID during fetal life have a lower cognitive development, compared to children to mothers taking daily tablet with vitamins and minerals, including 150 ug iodine during pregnancy.
The MAIN AIM of the SWIDDICH trial is to determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.
Read the detailed description
AIMS
- To determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.
- To investigate the interaction between iodine, selenium and iron, as components of the intervention.
- To compare urinary iodine concentration (UIC), thyroglobulin (Tg), free tetraiodothyronine (FT4) and thyroid stimulating hormone (TSH) in pregnant women on daily tablet with vitamins and minerals, including 150 µg iodine or placebo
- To compare milk iodine concentration (MIC) in colostrum, and TSH in the first 200 newborn children to pregnant women receiving daily tablet with vitamins and minerals, including 150 µg iodine or placebo
BACKGROUND Iodine deficiency increases the risk for hypothyroidism and goiter and during the pregnancy for abortion or cognitive and other abnormalities of the baby. According to the WHO recommendations, UIC during pregnancy should be 150-249 ug/L. In 2007 a national study showed iodine sufficiency in Swedish general population. It is debated whether or not iodine shall be given to pregnant women in iodine sufficient populations.
The research group started this randomized iodine intervention in pregnant women in 2012. The first hypothesis was that daily supplementation with a tablet with vitamins and minerals including 150 µg iodine is needed during pregnancy in Sweden in order to ensure normal iodine and thyroid hormone status in mothers and newborn children and that pregnant women in Sweden suffer from mild iodine deficiency (ID).
There is a substantial gap of knowledge with regards to whether mild ID during fetal life entails negative consequences on cognition. Two large observational studies have shown association between mild ID during pregnancy and lower IQ or educational performance in school-children. The only two randomized placebo-controlled trials (RCTs) studying mild ID in pregnancy were either too small for safe conclusions to be drawn ( Brucker-Davis et al, n=86), or did not manage to separate groups based on iodine levels (the MITCH study, Melse-Boonstra et al, n=839). The need for a RCT with sufficient sample size remains. This led the research team to form a second hypothesis within the trial: children exposed to deficient micronutrition including mild ID during fetal life have lower cognitive development compared to children to mothers taking a daily tablet with vitamins and minerals including150 ug iodine during pregnancy. The decision to expand the trial was made and the target number of participants to be recruited increased from 200 to 1275 in order to reach enough power to follow-up the childrens' cognitive development.
METHODS
Design
This is a prospective placebo-controlled trial of children whose mothers got iodine supplement 150 µg/day (a tablet with vitamins and minerals) or placebo (a multivitamin preparation without minerals) during pregnancy (week 10±2 until delivery). The target number participants during pregnancy is 1275 to enable sufficient power in the children follow-up (n=788). The main outcome is intelligence quotient (IQ) at 3.5 year of age. Cognitive development in children will be also assessed at 18 months, 7, and 14 years.
Pregnancy part
Pregnant women from more than ten maternity care centers in Sweden are randomized to daily receive a multivitamin tablet with minerals, including 150 µg iodine or placebo (multivitamin without iodine). The intervention starts at pregnancy week 8-12 and ends directly post-partum for the first 200 women and at pregnancy week 36±2weeks for the remaining participants. This time point may be adjusted to local circumstances, depending on when during the third trimester the routine visit at maternity care center takes place. Participants are included after the first visit by a midwife. Urine sample for UIC and U-creatinine, and blood sample for thyroid hormones, thyroid stimulating hormone (TSH), thyroglobuline (Tg) and thyroperoxidase antibodies (TPO-ab) are collected and a simple questionnaire is filled in at week 10±2 weeks of pregnancy and placebo/intervention is started. Selenium and iron are also measured. The same measurements are collected in week 25±1 week and week 36±2 weeks. Directly after delivery (within 5 days), MIC and UIC in the first 200 mother as well as UIC and TSH in their newborn child were collected and a simple questionnaire is filled in. Weight, length and APGAR in the child and pregnancy complications are registered. Blood is also frozen for future analyses and access to medical files is accepted.
In parallel 90 healthy female controls from Skaraborg area stratified for age and smoking habits are collected from a randomized sample attained by the Swedish Tax Agency. UIC, u-creatinine, FT4, TSH, Tg, TPO-ab, and samples to be frozen are collected and a questionnaire is filled in. Selenium and iron will be analyzed in blood sample from the first 200 pregnant women and from controls. The primary purpose for having a control population is to ascertain that the normal population in the area of Skaraborg is iodine sufficient.
Children follow-up
At 18 months ± 1 month psychomotor development is assessed by means of ASQ (Ages and Stages Questionnaire). At 3,5 years ± 2 months the IQ is measured (WPPSI-IV), behavior is assessed (CBCL questionnaire) and urine is collected for UIC measurement. At 7 years ± 3 months the following are assessed: IQ (WISC IV), motor development (Movement ABC), behavior (CBCL), symptoms related to attention deficit and hyperactivity disorder (ADHD, 5-15 Nordic questionnaire). Additionally, at 7 years ± 3 months urine is collected for UIC measurement, blood sample is taken for thyreoglobulin (Tg), thyroid hormones and deiodinases, and MRI of the brain is performed in a subsample. At 14 years ± 6 months all these, except for the Movement ABC, are repeated. On all occasions information on socio-economic status and other possible confounders are collected by means of questionnaires filled by parents and by children (14 years).
- Being tested
- Iodine, Placebo
- Keywords
- Iodine, Double-Blind Method, Randomized Controlled Tria, Cognitive Development
- Medical subject headings
- Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IodineDietary supplement
PlaceboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily | Experimental | Table of contents:
Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg Receives: Dietary Supplement: Iodine |
| Placebo: non-iodine containing multivitamin, 1 tablet daily | Placebo comparator | Table of contents:
Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intelligence quotient (IQ) at 3.5 years, WPPSI IV
Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition; IQ with sub-domains
Measured: when the child is at the age of 3,5 years ± 2 months
Secondary outcomes (50)
Psychomotor development at 18 months, ASQ-3
Ages \& Stages Questionnaire - Third Edition; a questionnaire filled in by parents
Measured: when the child is at the age of 18 months ± 1 month
Intelligence quotient (IQ) at 7 years, WISC IV
Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains
Measured: when the child is at the age of 7 years ± 3 months
Intelligence quotient (IQ) at 14 years, WISC IV
Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains
Measured: when the child is at the age of 14 years ± 6 months
Behavioral problems at 3.5 years, CBCL
Child Behavior Checklist questionnaire filled in by parents
Measured: when the child is at the age of 3,5 years ± 2 months
Behavioral problems at 7 years, CBCL
Child Behavior Checklist questionnaire filled in by parents
Measured: when the child is at the age of 7 years ± 3 months
Behavioral problems at 14 years, CBCL
Child Behavior Checklist questionnaire filled in by parents
Measured: when the child is at the age of 14 years ± 6 months
ADHD-related problems at 7 years, FTF
Nordic Questionnaire 5-15 (FTF) filled in by parents
Measured: when the child is at the age of 7 years ± 3 months
ADHD-related problems at 14 years, FTF
Nordic Questionnaire 5-15 (FTF) filled in by parents
Measured: when the child is at the age of 14 years ± 6 months
Motor skills at 7 years, Movement ABC
Movement ABC test performed by a physiotherapist
Measured: when the child is at the age of 7 years ± 3 months
Brain development at 7 years, MRI
Magnetic Resonance Imaging; manual and automatic volumetry
Measured: when the child is at the age of 7 years ± 3 months
Brain development at 7 years, MRI
Magnetic Resonance Imaging; manual and automatic volumetry
Measured: when the child is at the age of 14 years ± 6 months
Urinary iodine concentration (UIC) in the mother, 1st trimester
Measured: 10±2 weeks (pregnancy)
Urinary iodine concentration (UIC) in the mother, 2nd trimester
Measured: 26±2 weeks (pregnancy)
Urinary iodine concentration (UIC) in the mother, 3rd trimester
Measured: 36±2 weeks (pregnancy)
Thyreoglobulin concentration in serum, in the mother, 1st trimester
Measured: 10±2 weeks (pregnancy)
Thyreoglobulin in serum, in the mother, 2nd trimester
Measured: 26±2 weeks (pregnancy)
Thyreoglobulin in serum, in the mother, 3rd trimester
Measured: 36±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 1st trimester
Measured: 10±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 2nd trimester
Measured: 26±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 3rd trimester
Measured: 36±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 1st trimester
Measured: 10±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 2nd trimester
Measured: 26±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 3rd trimester
Free thyroxine concentration, serum
Measured: 36±2 weeks (pregnancy)
Anti-TPO in the mother, 1st trimester
Thyroid peroxidase antibody titer, plasma
Measured: 10±2 weeks (pregnancy)
Anti-TPO in the mother, 2nd trimester
Thyroid peroxidase antibody titer, plasma
Measured: 26±2 weeks (pregnancy)
Anti-TPO in the mother, 3rd trimester
Thyroid peroxidase antibody titer, plasma
Measured: 36±2 weeks (pregnancy)
B12 in the mother, 1st trimester
Vitamin B12, serum
Measured: 10±2 weeks (pregnancy)
B12 in the mother, 2nd trimester
Vitamin B12, serum
Measured: 26±2 weeks (pregnancy)
B12 in the mother, 3rd trimester
Vitamin B12, serum
Measured: 36±2 weeks (pregnancy)
Selenium in the mother, 1st trimester
Selenium, serum
Measured: 10±2 weeks (pregnancy)
Selenium in the mother, 2nd trimester
Selenium, serum
Measured: 26±2 weeks (pregnancy)
Selenium in the mother, 3rd trimester
Selenium, serum
Measured: 36±2 weeks (pregnancy)
Iron in the mother, 1st trimester
Iron, serum
Measured: 10±2 weeks (pregnancy)
Iron in the mother, 2nd trimester
Iron, serum
Measured: 26±2 weeks (pregnancy)
Iron in the mother, 3rd trimester
Iron, serum
Measured: 36±2 weeks (pregnancy)
Milk iodine concentration (MIC) in colostrum
Measured: within 5 days after delivery
Urinary iodine concentration (UIC) in the newborn
Measured: within 5 days after delivery
Urinary iodine concentration (UIC) in the mother
Measured: within 5 days after delivery
Urinary iodine concentration (UIC) at 3.5 years
Measured: when the child is at the age of 3,5 years ± 2 months
Urinary iodine concentration (UIC) at 7 years
Measured: when the child is at the age of 7 years ± 3 months
Urinary iodine concentration (UIC) at 14 years
Measured: when the child is at the age of 14 years ± 6 months
Thyroid stimulating hormone, dry blood spot (DBS), in the newborn
Measured: within 5 days after delivery
TSH at 7 years
Thyroid stimulating hormone, dry blood spot (DBS)
Measured: when the child is at the age of 7 years ± 3 months
TSH at 14 years
Thyroid stimulating hormone, dry blood spot (DBS)
Measured: when the child is at the age of 14 years ± 6 months
TG at 7 years
Thyreoglobulin, dry blood spot (DBS)
Measured: when the child is at the age of 7 years ± 3 months
TG at 14 years
Thyreoglobulin, dry blood spot (DBS)
Measured: when the child is at the age of 14 years ± 6 months
FT4 at 7 years
Free thyroxine, dry blood spot (DBS)
Measured: when the child is at the age of 7 years ± 3 months
FT4 at 14 years
Free thyroxine, dry blood spot (DBS)
Measured: when the child is at the age of 14 years ± 6 months
Deiodinases at 7 years
Dry blood spot (DBS)
Measured: when the child is at the age of 7 years ± 3 months
Deiodinases at 14 years
Dry blood spot (DBS)
Measured: when the child is at the age of 14 years ± 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2015 (estimated)
- Study startNov 2012
- Primary completionJun 2029 (estimated)
- Study completionJun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Thyroid Gland; NodeStudies of the same condition, open and under way.
- More trials run by Göteborg UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 1,337 participants (actual)
Sponsor and investigators
- Lead sponsor
- Göteborg University
- Sponsor type
- University, hospital or other
- Collaborators
- Sahlgrenska University Hospital
- Responsible party
- Sponsor
- Investigators
- Helena Filipsson Nyström, Ass Prof, Principal investigator, Center for Endocrinology and Metabolism, SAhlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02378246
- Sponsor's protocol ID
- 13031305
- Acronym
- SWIDDICH
- Status last verified
- Mar 2025
- First submitted
- 19 Jan 2015
- Last updated
- 26 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided: This has not yet been discussed by the study group.
Publications
Manousou S, Eggertsen R, Hulthen L, Filipsson Nystrom H. A randomized, double-blind study of iodine supplementation during pregnancy in Sweden: pilot evaluation of maternal iodine status and thyroid function. Eur J Nutr. 2021 Sep;60(6):3411-3422. doi: 10.1007/s00394-021-02515-1. Epub 2021 Feb 23.
PubMed 33620551Manousou S, Johansson B, Chmielewska A, Eriksson J, Gutefeldt K, Tornhage CJ, Eggertsen R, Malmgren H, Hulthen L, Domellof M, Nystrom Filipsson H. Role of iodine-containing multivitamins during pregnancy for children's brain function: protocol of an ongoing randomised controlled trial: the SWIDDICH study. BMJ Open. 2018 Apr 10;8(4):e019945. doi: 10.1136/bmjopen-2017-019945.
PubMed 29643159
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study
- ClinicalTrials.gov ID
- NCT02378246
- Acronym / sponsor ID
- SWIDDICH / 13031305
- Keywords
- Iodine, Double-Blind Method, Randomized Controlled Tria, Cognitive Development
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,337 participants (actual)
- Lead sponsor
- Göteborg UniversityUniversity, hospital or other
- Collaborators
- Sahlgrenska University Hospital
- Study start
- Nov 2012 (actual)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2032 (estimated)
- First posted
- 4 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should a tablet with vitamins and minerals, including 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID and no extra iodine is needed?". To answer this question, the investigators planned a randomized, placebo-controlled trial of micronutrient supplementation during pregnancy in Sweden (SWIDDICH) with the follow-up of childrens' COGNITIVE DEVELOPMENT at 18 months, 3.5, 7 and 14 years.
Iodine deficiency (ID) is associated with thyroid morbidity and, especially in children, with impaired cognitive development. Sweden introduced iodine fortification of table salt 1936 and mental retardation due to severe ID is eradicated. Is mild ID during pregnancy also eradicated? If not, is this of importance? A national study performed by the investigators in 2007 showed iodine sufficiency in general population, but there are no pregnancy data. Local studies have raised concerns for mild ID during pregnancy in Sweden and a trans-sectional national study is currently ongoing.
The burning question for Sweden and the whole world is: is mild ID during pregnancy of importance for the developing brain of the fetus? Two large observational studies have shown association between mild ID during pregnancy and lower verbal IQ or educational performance at school-aged children. The world needs a randomized placebo-controlled trial (RTC) comparing the cognitive outcome in children exposed to mild ID during fetal life with children exposed to normal iodine levels during fetal life.
Our HYPOTHESIS is that pregnant women in Sweden have mild ID and that children exposed to mild ID during fetal life have a lower cognitive development, compared to children to mothers taking daily tablet with vitamins and minerals, including 150 ug iodine during pregnancy.
The MAIN AIM of the SWIDDICH trial is to determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.
Detailed description
AIMS
- To determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.
- To investigate the interaction between iodine, selenium and iron, as components of the intervention.
- To compare urinary iodine concentration (UIC), thyroglobulin (Tg), free tetraiodothyronine (FT4) and thyroid stimulating hormone (TSH) in pregnant women on daily tablet with vitamins and minerals, including 150 µg iodine or placebo
- To compare milk iodine concentration (MIC) in colostrum, and TSH in the first 200 newborn children to pregnant women receiving daily tablet with vitamins and minerals, including 150 µg iodine or placebo
BACKGROUND Iodine deficiency increases the risk for hypothyroidism and goiter and during the pregnancy for abortion or cognitive and other abnormalities of the baby. According to the WHO recommendations, UIC during pregnancy should be 150-249 ug/L. In 2007 a national study showed iodine sufficiency in Swedish general population. It is debated whether or not iodine shall be given to pregnant women in iodine sufficient populations.
The research group started this randomized iodine intervention in pregnant women in 2012. The first hypothesis was that daily supplementation with a tablet with vitamins and minerals including 150 µg iodine is needed during pregnancy in Sweden in order to ensure normal iodine and thyroid hormone status in mothers and newborn children and that pregnant women in Sweden suffer from mild iodine deficiency (ID).
There is a substantial gap of knowledge with regards to whether mild ID during fetal life entails negative consequences on cognition. Two large observational studies have shown association between mild ID during pregnancy and lower IQ or educational performance in school-children. The only two randomized placebo-controlled trials (RCTs) studying mild ID in pregnancy were either too small for safe conclusions to be drawn ( Brucker-Davis et al, n=86), or did not manage to separate groups based on iodine levels (the MITCH study, Melse-Boonstra et al, n=839). The need for a RCT with sufficient sample size remains. This led the research team to form a second hypothesis within the trial: children exposed to deficient micronutrition including mild ID during fetal life have lower cognitive development compared to children to mothers taking a daily tablet with vitamins and minerals including150 ug iodine during pregnancy. The decision to expand the trial was made and the target number of participants to be recruited increased from 200 to 1275 in order to reach enough power to follow-up the childrens' cognitive development.
METHODS
Design
This is a prospective placebo-controlled trial of children whose mothers got iodine supplement 150 µg/day (a tablet with vitamins and minerals) or placebo (a multivitamin preparation without minerals) during pregnancy (week 10±2 until delivery). The target number participants during pregnancy is 1275 to enable sufficient power in the children follow-up (n=788). The main outcome is intelligence quotient (IQ) at 3.5 year of age. Cognitive development in children will be also assessed at 18 months, 7, and 14 years.
Pregnancy part
Pregnant women from more than ten maternity care centers in Sweden are randomized to daily receive a multivitamin tablet with minerals, including 150 µg iodine or placebo (multivitamin without iodine). The intervention starts at pregnancy week 8-12 and ends directly post-partum for the first 200 women and at pregnancy week 36±2weeks for the remaining participants. This time point may be adjusted to local circumstances, depending on when during the third trimester the routine visit at maternity care center takes place. Participants are included after the first visit by a midwife. Urine sample for UIC and U-creatinine, and blood sample for thyroid hormones, thyroid stimulating hormone (TSH), thyroglobuline (Tg) and thyroperoxidase antibodies (TPO-ab) are collected and a simple questionnaire is filled in at week 10±2 weeks of pregnancy and placebo/intervention is started. Selenium and iron are also measured. The same measurements are collected in week 25±1 week and week 36±2 weeks. Directly after delivery (within 5 days), MIC and UIC in the first 200 mother as well as UIC and TSH in their newborn child were collected and a simple questionnaire is filled in. Weight, length and APGAR in the child and pregnancy complications are registered. Blood is also frozen for future analyses and access to medical files is accepted.
In parallel 90 healthy female controls from Skaraborg area stratified for age and smoking habits are collected from a randomized sample attained by the Swedish Tax Agency. UIC, u-creatinine, FT4, TSH, Tg, TPO-ab, and samples to be frozen are collected and a questionnaire is filled in. Selenium and iron will be analyzed in blood sample from the first 200 pregnant women and from controls. The primary purpose for having a control population is to ascertain that the normal population in the area of Skaraborg is iodine sufficient.
Children follow-up
At 18 months ± 1 month psychomotor development is assessed by means of ASQ (Ages and Stages Questionnaire). At 3,5 years ± 2 months the IQ is measured (WPPSI-IV), behavior is assessed (CBCL questionnaire) and urine is collected for UIC measurement. At 7 years ± 3 months the following are assessed: IQ (WISC IV), motor development (Movement ABC), behavior (CBCL), symptoms related to attention deficit and hyperactivity disorder (ADHD, 5-15 Nordic questionnaire). Additionally, at 7 years ± 3 months urine is collected for UIC measurement, blood sample is taken for thyreoglobulin (Tg), thyroid hormones and deiodinases, and MRI of the brain is performed in a subsample. At 14 years ± 6 months all these, except for the Movement ABC, are repeated. On all occasions information on socio-economic status and other possible confounders are collected by means of questionnaires filled by parents and by children (14 years).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily | Experimental | Dietary Supplement: IodineTable of contents: Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg |
| Placebo: non-iodine containing multivitamin, 1 tablet daily | Placebo comparator | Dietary Supplement: PlaceboTable of contents: Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Pregnant, week <13
- Age 18-40 years
- Intent of a full term pregnancy
- Agreement of taking no iodide containing supplements during the study except for study supplement
- Age 18-40 years
Key exclusion criteria (12 listed)
- Known current thyroid disease
- Risk factors for thyroid disease (history or heredity for thyroid, other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
- Possibility to not attend to the protocol according to the investigator's opinion
- Less than 6 months from previous pregnancy or lactating period
- Vegan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Iodine | Dietary supplement | Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily |
| Placebo | Dietary supplement | Placebo: non-iodine containing multivitamin, 1 tablet daily |
Primary outcome
Intelligence quotient (IQ) at 3.5 years, WPPSI IV
Time frame: when the child is at the age of 3,5 years ± 2 months
Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition; IQ with sub-domains
50 secondary outcomes
Psychomotor development at 18 months, ASQ-3
Time frame: when the child is at the age of 18 months ± 1 month
Intelligence quotient (IQ) at 7 years, WISC IV
Time frame: when the child is at the age of 7 years ± 3 months
Intelligence quotient (IQ) at 14 years, WISC IV
Time frame: when the child is at the age of 14 years ± 6 months
Behavioral problems at 3.5 years, CBCL
Time frame: when the child is at the age of 3,5 years ± 2 months
Behavioral problems at 7 years, CBCL
Time frame: when the child is at the age of 7 years ± 3 months
Behavioral problems at 14 years, CBCL
Time frame: when the child is at the age of 14 years ± 6 months
ADHD-related problems at 7 years, FTF
Time frame: when the child is at the age of 7 years ± 3 months
ADHD-related problems at 14 years, FTF
Time frame: when the child is at the age of 14 years ± 6 months
Motor skills at 7 years, Movement ABC
Time frame: when the child is at the age of 7 years ± 3 months
Brain development at 7 years, MRI
Time frame: when the child is at the age of 7 years ± 3 months
Brain development at 7 years, MRI
Time frame: when the child is at the age of 14 years ± 6 months
Urinary iodine concentration (UIC) in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Urinary iodine concentration (UIC) in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Urinary iodine concentration (UIC) in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Thyreoglobulin concentration in serum, in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Thyreoglobulin in serum, in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Thyreoglobulin in serum, in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Thyroid stimulating hormon concentration in serum, in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Free thyroxine concentration in serum, in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Anti-TPO in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Anti-TPO in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Anti-TPO in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
B12 in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
B12 in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
B12 in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Selenium in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Selenium in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Selenium in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Iron in the mother, 1st trimester
Time frame: 10±2 weeks (pregnancy)
Iron in the mother, 2nd trimester
Time frame: 26±2 weeks (pregnancy)
Iron in the mother, 3rd trimester
Time frame: 36±2 weeks (pregnancy)
Milk iodine concentration (MIC) in colostrum
Time frame: within 5 days after delivery
Urinary iodine concentration (UIC) in the newborn
Time frame: within 5 days after delivery
Urinary iodine concentration (UIC) in the mother
Time frame: within 5 days after delivery
Urinary iodine concentration (UIC) at 3.5 years
Time frame: when the child is at the age of 3,5 years ± 2 months
Urinary iodine concentration (UIC) at 7 years
Time frame: when the child is at the age of 7 years ± 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2025.
- Derived from this study: PubMed 33620551Manousou S, Eggertsen R, Hulthen L, Filipsson Nystrom H. A randomized, double-blind study of iodine supplementation during pregnancy in Sweden: pilot evaluation of maternal iodine status and thyroid function. Eur J Nutr. 2021 Sep;60(6):3411-3422. doi: 10.1007/s00394-021-02515-1. Epub 2021 Feb 23.
- Derived from this study: PubMed 29643159Manousou S, Johansson B, Chmielewska A, Eriksson J, Gutefeldt K, Tornhage CJ, Eggertsen R, Malmgren H, Hulthen L, Domellof M, Nystrom Filipsson H. Role of iodine-containing multivitamins during pregnancy for children's brain function: protocol of an ongoing randomised controlled trial: the SWIDDICH study. BMJ Open. 2018 Apr 10;8(4):e019945. doi: 10.1136/bmjopen-2017-019945.
- Individual participant dataSharing planned: Undecided. This has not yet been discussed by the study group.
Related trials for Thyroid Gland; Node
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingObservational study
Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid Cancer
Medullary Thyroid Carcinoma
Not yet recruitingObservational study
Thyroid Health Outcomes Registry for Surgery
Thyroid Diseases, Thyroid Neoplasms
Recruiting
Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospective Multicenter Single-Arm Study
Thyroid Cancer Patients, Lymph Node Metastasis
Not yet recruitingPhase 1/2
FAPI PET Imaging - An Exploratory Study
Thyroid Pathology, Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helena Filipsson Nyström, Ass Prof principal investigator
Center for Endocrinology and Metabolism, SAhlgrenska University Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Iodine in people with Thyroid Gland; Node and Pregnancy, run by Göteborg University at 4 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intelligence quotient (IQ) at 3.5 years, WPPSI IV (time frame: when the child is at the age of 3,5 years ± 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02378246, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2025.